



A trusted technology partner

JUNE 2026



Safe Harbor Statement

Certain statements in this presentation are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as “expect,” “intend,” “anticipate,” “estimate,” “believe,” “future,” “could,” “should,” “plan,” “aim,” and other similar expressions. These forward-looking statements include, but are not limited to, statements regarding anticipated financial performance and financial position, including our financial outlook for the full year of 2026; expectations for our end markets and market position; macroeconomic expectations; our competitive position, including our positioning for long-term growth capital spending and momentum from new product launches; and other statements that are not historical facts.

These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various important factors, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our businesses and on our customers’ businesses, capital expenditures and level of business activities; our dependence upon our ability to respond to fluctuations in product demand; our ability to continuously innovate, to introduce new products in a timely manner, and to manage transitions to new product innovations effectively; customer order timing and other similar factors; disruptions or breaches in security of our or our third-party providers’ information technology systems; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; our ability to contain or reduce costs; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business; our ability to attract and retain key personnel; our restructuring and realignment activities; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components and other goods from our suppliers; our failure to accurately forecast component and raw material requirements leading to additional costs and significant delays in shipments; production difficulties and product delivery delays or disruptions; our exposure to extensive medical device regulations, which may impede or hinder the approval, certification or sale of our products and, in some cases, may ultimately result in an inability to obtain approval or certification of certain products or may result in the recall or seizure of previously approved or certified products; potential penalties for violating foreign and U.S. federal and state healthcare laws and regulations; impact of healthcare industry cost containment and healthcare reform measures; changes in governmental regulations related to our business or products; actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards, and other requirements; our failure to implement new information technology systems successfully; changes in foreign currency rates; our failure to realize the full value of our intangible assets; our reliance on original equipment manufacturer customers; the loss of sales, or significant reduction in orders from, any major customers; increasing scrutiny and changing expectations from investors, customers, governments and other stakeholders and third parties with respect to corporate sustainability policies and practices; the effects of climate change and related regulatory responses; our exposure to the credit risk of some of our customers and in weakened markets; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; changes in tax laws and fluctuations in our effective tax rates; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; our existing indebtedness limiting our ability to engage in certain activities; volatility in the market price for our common shares; and our failure to maintain appropriate internal controls in the future.

Any or all of our forward-looking statements may turn out to be inaccurate, and there are no guarantees about our performance. The factors identified above are not exhaustive. We operate in a dynamic business environment in which new risks may emerge frequently. Accordingly, you should not place undue reliance on forward-looking statements, which speak only as of the dates on which they are made. In addition, results for prior periods are not necessarily indicative of results that may be expected for any future period.

Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and as further updated by our subsequent filings with the Securities and Exchange Commission. Such statements are based on the Company’s beliefs and assumptions and on information currently available to the Company. The Company disclaims any obligation to publicly update or revise any such forward-looking statements as a result of developments occurring after the date of this document except as required by law.

In this presentation, we present the non-GAAP financial measure of Adjusted EBITDA. Please see “Use of Non-GAAP Financial Measures” in the accompanying appendix and our most recent earnings press release for the reasons why we use this measure, a reconciliation of this measure to the most directly comparable GAAP measures, and other information relating to this measure.

We accelerate innovation and productivity for leading global OEMs in attractive markets

BUSINESS MODEL FOCUS

- ✓ Differentiated long-term OEM supplier
- ✓ Win in high-growth end markets, with leading OEMs
- ✓ Sole-source customized solutions, with proprietary IP
- ✓ Delivering sustainable & leverageable cash flows

FINANCIAL PROFILE

\$981M

Revenue

\$221M

Adjusted EBITDA
+22% of sales

53%


Sales to Medical markets

~\$7B



Addressable market with
5% – 7% CAGR



Novanta's growth runs on self-sustaining momentum



We're entering the next phase in our transformation journey



Expanding business mix to medical, consumables & embedded software


We're pursuing innovative growth platforms in attractive markets

+\$4B

of additional market opportunity by 2030



**Precision
Medicine**




**Scan
Systems**



**Physical
AI**



**Robotic
Surgery**



**Pumps &
Insufflators**

Expanding our market leadership in gas and fluid management

WHY NOVANTA WINS

- Market leader in smoke evacuation insufflation
- Proprietary algorithms and sensing in fluid & flow management
- Expanding into arthroscopy pumps with same customers



MARKET OPPORTUNITY

\$1B market size by 2030

Double-digit long-term market growth rate



SMART PUMPS

integrated smoke evacuation and insufflation enhance OR safety and efficiency

2X

business will double in size from 2024 to 2030

We've established a strong capability as a supplier of medical consumables

WHY NOVANTA WINS

- Current product offerings have grown to become ~15% of company sales
- Strong manufacturing and engineering competency
- Seen by our partners as a good supplier, creating a good pedestal to jump off into other consumables categories



MARKET OPPORTUNITY

Double-digit growth rate in medical consumables

Per procedure usage, driving recurring revenue stream



MEDICAL CONSUMABLES

innovative, high-quality consumables for surgical procedures

We're a leading supplier for robotic surgery applications

WHY NOVANTA WINS


- Customized unique solutions, partnering with multiple OEMs
- Insufflation leadership, integrated with surgical robot systems
- Position and force/torque sensing, and smart motion control, contributing to successful robotic surgical procedures



MARKET OPPORTUNITY

\$1B market size by 2030

Double-digit long-term market growth rate



FLUID/GAS
MANAGEMENT
SOLUTIONS

PRECISION
MOTION
for robotic
surgery

~10%
of all
procedures
done robotically

Our proprietary physical AI robotics solutions are focused on advanced safety and sensing

WHY NOVANTA WINS

- Integrated safety with best-in-class dexterity
- Compact and lightweight, with high power efficiency
- Unique customer solutions
- Partnering with leading humanoid and warehouse automation players in North America & Europe




MARKET OPPORTUNITY

\$1B market size by 2030

Double-digit long-term market growth rate

Accelerated penetration driven by Gen AI



MOTION CONTROL

precise motion via miniaturized drives, custom motors & mechatronics

SENSING

measuring position and providing a sense of touch

We help automate & optimize manufacturing through advanced beam steering

WHY NOVANTA WINS

- Never-before possible throughput, precision & miniaturization
- Proprietary integrated solution of hardware and software
- Increasing \$ content and stickiness with customers through intelligent subsystem products



MARKET OPPORTUNITY

\$0.4B market size by 2030

High single-digit long-term market growth rate



Our solutions drive productivity, improve patient outcomes, and support early disease detection

WHY NOVANTA WINS

- Supporting clinical adoption of advanced multi-omics applications
- Enabling automation and cutting-edge capabilities for precision medicine equipment
- Transform disease research, drug discovery & clinical development



MARKET OPPORTUNITY

\$0.5B market size by 2030

High single-digit long-term market growth rate



PRECISION MOTION

sample movement & alignment

RFID READER

reagent & sample tracking

MACHINE VISION


sample scanning & analysis

LIGHT ENGINE


optical sub-system solutions



High-performance culture is our competitive advantage



Compound cash flows through attractive acquisitions



ACQUISITION TRACK RECORD

~**\$1.2B** Capital deployed **21** Transactions

LONG-TERM ACQUISITION PIPELINE


+\$15B Aggregate revenue

STRATEGIC CRITERIA


Commercial Synergies	Secular Growing	Cash Accretive
Technologies or end markets	Organic growth	NGS-driven + ROIC

And delivers consistently strong financial results

REVENUE



ADJUSTED EBITDA



FINANCIAL FRAMEWORK

Mid- to high-single-digit **organic growth**

Double-digit reported growth **through acquisitions**

100 bps per year of **gross margin expansion**

Strong **free cash flow** generation > 100% of net income

We deliver innovation
that matters



Use of non-GAAP measures

The non-GAAP financial measures used in this presentation are Adjusted EBITDA.

The Company believes that this non-GAAP financial measures provides useful and supplementary information to investors regarding the operating performance of the Company. It is management's belief that this non-GAAP financial measures would be particularly useful to investors because of the significant changes that have occurred outside of the Company's day-to-day business in accordance with the execution of the Company's strategy. This strategy includes streamlining the Company's existing operations through site and functional consolidations, strategic divestitures and product line closures, expanding the Company's business through significant internal investments, and broadening the Company's product and service offerings through acquisitions of innovative and complementary technologies and solutions. The financial impact of certain elements of these activities, particularly acquisitions, divestitures, and site and functional restructurings, is often large relative to the Company's overall financial performance and can adversely affect the comparability of its operating results and investors' ability to analyze the business from period to period.

The Company defines Adjusted EBITDA as income before deducting interest (income) expense, income tax provision (benefit), depreciation, amortization, non-cash share-based compensation, inventory fair value adjustments related to business acquisitions, inventory related charges associated with product line closures, restructuring, acquisition and related costs, discrete costs related to the planning and design phase of a Financial and Operation system implementation, charges related to an insurance recovery, officer transition costs, operational transformation costs, EU medical device regulation charges, and other non-operating (income) expense items, including foreign exchange transaction (gains) losses, costs related to our debt refinancing and net periodic pension costs of the Company's frozen U.K. defined benefit pension plan.

The Company's Adjusted EBITDA is used by management to evaluate operating performance, communicate financial results to the Board of Directors, benchmark results against historical performance and the performance of peers, and evaluate investment opportunities, including acquisitions and divestitures. In addition, Adjusted EBITDA is a financial performance metric used to determine bonus payments for senior management and employees. Accordingly, the Company believes that this non-GAAP financial measure provides greater transparency and insight into management's method of analysis.

Non-GAAP financial measures should not be considered as substitutes for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on the Company's reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company's financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this presentation.

Novanta provides earnings guidance on a non-GAAP basis and does not provide earnings guidance on a GAAP basis, with the exception of GAAP revenue guidance. A reconciliation of the Company's forward-looking Adjusted EBITDA guidance to the most directly comparable GAAP financial measures is not provided because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including acquisitions and related expenses; impact of purchase price allocations for recently completed acquisitions; future changes in the fair value of contingent considerations; future restructuring expenses; divestitures and related expenses; gains and losses from sale of real estate assets; costs related to product line closures; intangible asset impairment charges and related asset write-offs; and other charges reflected in the Company's reconciliation of historical non-GAAP financial measures, the amounts of which, based on past experience, could be material.

Non-GAAP reconciliation

TWELVE MONTHS ENDED

THREE MONTHS ENDED

(in thousands of dollars)

REVENUE

	Dec 31, 2012	Dec 31, 2013	Dec 31, 2014	Dec 31, 2015	Dec 31, 2016	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Apr 3, 2026
Revenue (GAAP)	\$243,796	\$316,910	\$364,706	\$373,598	\$384,758	\$521,290	\$614,337	\$626,099	\$590,623	\$706,793	\$860,903	\$881,662	\$949,245	\$980,600	\$257,707

ADJUSTED EBITDA

	Dec 31, 2012	Dec 31, 2013	Dec 31, 2014	Dec 31, 2015	Dec 31, 2016	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Apr 3, 2026
Operating income (loss) from continuing operations (GAAP)	\$20,798	\$19,951	(\$16,729)	\$29,304	\$32,955	\$57,566	\$71,013	\$55,282	\$55,888	\$64,054	\$103,079	\$110,496	\$110,584	\$94,012	\$27,539
Depreciation and amortization	12,458	19,570	23,797	19,114	20,357	30,758	37,052	38,280	38,293	43,126	53,158	46,612	55,563	61,932	14,160
Share-based compensation	4,534	5,442	4,329	4,387	4,293	5,493	7,647	9,340	22,535	22,557	23,108	25,588	23,307	29,538	9,796
Impairment of goodwill and intangible assets	-	-	41,442	-	-	-	-	-	-	-	-	-	-	-	-
Restructuring, acquisition, divestiture and other costs	4,369	5,387	3,091	8,273	7,945	7,542	8,041	16,574	3,810	18,020	4,384	13,060	13,714	20,442	2,098
Inventory related charges associated with product line closures	-	-	-	-	1,370	-	-	-	-	-	-	473	2,493	65	-
Acquisition fair value adjustments	-	965	596	358	205	4,754	-	1,270	188	1,411	160	-	2,777	-	-
Officer transition costs	-	-	-	-	1,306	-	-	-	-	-	-	-	1,411	1,137	-
Employee COVID-19 testing costs	-	-	-	-	-	-	-	-	275	3,568	240	-	-	-	-
Costs incurred for insurance recovery claim	-	-	-	-	-	-	-	-	-	-	-	-	-	6,220	-
Planning and design phase of financial and operation system implementation	-	-	-	-	-	-	-	-	-	-	-	-	-	7,604	2,658
Operational transformation costs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	556
EU medical device regulation charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-	269
Adjusted EBITDA (Non-GAAP)	\$42,159	\$51,315	\$56,526	\$61,436	\$68,431	\$106,113	\$123,753	\$120,746	\$120,989	\$152,736	\$184,129	\$196,229	\$209,849	\$220,950	\$57,076

Our businesses align to end-market growth themes



PRECISION MANUFACTURING



ROBOTICS AND AUTOMATION



ADVANCED SURGERY




PRECISION MEDICINE


Key Applications



Advanced material processing



Metal-based additive manufacturing



Factory, warehouse & lab automation




Medical & industrial robotics



Robotic surgery procedures



Minimally invasive surgery procedures





Genomics, proteomics & spatial biology



In vitro diagnostics & lab automation

Revenue segmentation



(1) Figures are as of December 31, 2025

(2) Growth profiles are based on management estimates.